Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Active, not recruiting Not applicable

Effect of Emotional Freedom Technique on Surgical Fear and Vital Signs in Women Undergoing Cesarean Section

NCT07156279 · tracked via the Priya Life Science Turkey tracker
Sponsor
Bingol University
Phase
Not applicable
Started
2025-03-01
Last updated
2025-09-05

Condition(s) studied

Cesarean SectionPreoperative Anxiety

Investigational drug(s) / intervention(s)

EFT(Emotional Freedom Technique)

EFT(Emotional Freedom Technique): EFT is a behavioral intervention in which participants tap with their fingertips on specific acupressure points while focusing on a target issue. The technique is non-invasive, painless, and simple to apply. Sessions also include the use of positive affirmations during tapping.

Study summary

Surgical interventions are unusual interventions that can cause anxiety and fear in individuals. It is known that anxiety and fear experienced during this period affect the intraoperative and postoperative process. Emotional Freedom Technique (EFT) is a type of energy psychotherapy that has no side effects and its effect on fear has been demonstrated in many studies. This study will be conducted to determine the effect of Emotional Freedom Technique (EFT) applied in the preoperative period in pregnant women planned to have a cesarean section on surgical fear, intraoperative hemodynamics and newborn Apgar score.

Research questions:

1. Does EFT Technique reduce surgical fear level?
2. Does EFT Technique affect intraoperative hemodynamics?
3. Is EFT Technique effective on newborn Apgar score?
4. Is there a relationship between surgical fear and intraoperative hemodynamics and newborn Apgar score? The research will be conducted in two stages in the Gynecology and Obstetrics Department of Bingöl State Hospital and the operating room unit of the same hospital. The universe of the study will consist of women who are scheduled for elective cesarean delivery and who do not have a risky pregnancy and who are admitted to Bingöl State Hospital. Considering the possibility of data loss due to various reasons during the study process, it is planned to be completed on a total of 60 women, 30 in the experimental group and 30 in the control group.

Eligibility

Sex
FEMALE
Min age
20 Years
Max age
40 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Those who volunteer to participate in the study, * Those who can understand and speak Turkish, * Those who are ASA II in the American Anesthesiologists Association risk classification, * Pregnant women who will undergo elective CS, * Women without a risky pregnancy (gestational diabetes mellitus, preeclampsia, eclampsia, HT patients, CHD, etc., multiple pregnancy, pregnancy with in vitro treatment), * Pregnant women between the ages of 20-40, * Pregnant women without any psychiatric comorbidities, * Pregnant women with a Fear score below 0 according to the SUE Scale. (Pregnant women who state that they are afraid of surgical procedures) Exclusion Criteria: * Those with serious heart, lung, liver disease, kidney failure, bleeding diathesis, fever, infection, allergy to the drugs to be used, * Patients with hypothermia and acid-base disorders and electrolyte disorders, * Those taking antibiotics, anticonvulsants, antiarrhythmics, cholinesterase inhibitors, * Pregnant women who decide to undergo general anesthesia for various reasons, * Pregnant women at risk,

Primary outcome measure(s)

  • Change in Surgical Fear Score (Surgical Fear Scale, total) — From baseline preoperative assessment on the day of surgery (after hospital admission and before EFT application) to thirty minutes after the EFT session, within the same preoperative day before transfer to the operating room.
    Change in the total score of the 8-item Surgical Fear Scale (range 0-80; each item scored 0-10). Scores will be assessed before and immediately after the EFT session in the intervention group, and at equivalent time points in the control group. Reporting will be done as the change score between the two time points and/or as a percentage change.

Trial sites (1)

FacilityCityRegionStatus
Bingöl Üniversitesi Bingoel Turkey (Türkiye)
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07156279 on ClinicalTrials.gov ↗ ← All trials in Turkey